We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

138 hedge funds and large institutions have $1.9B invested in Ventyx Biosciences in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 61 increasing their positions, 44 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 44

10% more capital invested

Capital invested by funds: $1.73B → $1.9B (+$169M)

2.78% more ownership

Funds ownership: 89.91%92.69% (+2.8%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

9% less call options, than puts

Call options by funds: $9.34M | Put options by funds: $10.3M

8% less funds holding

Funds holding: 150138 (-12)

43% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 23

Holders
138
Holders Change
-12
Holders Change %
-8%
% of All Funds
2.19%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
13
Increased
61
Reduced
44
Closed
23
Calls
$9.34M
Puts
$10.3M
Net Calls
-$921K
Net Calls Change
+$23.5M
Name Holding Trade Value Shares
Change
Change in
Stake
AA
101
AlphaCentric Advisors
Puerto Rico
$417K +$415K +12,000 New
ASRS
102
Arizona State Retirement System
Arizona
$405K +$36.1K +1,043 +10%
Teacher Retirement System of Texas
103
Teacher Retirement System of Texas
Texas
$404K +$47.6K +1,376 +13%
AC
104
Avestar Capital
New York
$396K +$35.7K +1,033 +10%
QT
105
Quantbot Technologies
New York
$381K -$282K -8,155 -43%
PA
106
Profund Advisors
Maryland
$373K -$55.7K -1,612 -13%
Citigroup
107
Citigroup
New York
$352K -$1.23M -35,507 -78%
DnB Asset Management
108
DnB Asset Management
Norway
$349K -$29.9K -865 -8%
ProShare Advisors
109
ProShare Advisors
Maryland
$345K +$1.87K +54 +0.5%
EWM
110
Evercore Wealth Management
New York
$277K +$28.3K +819 +11%
Zurich Cantonal Bank
111
Zurich Cantonal Bank
Switzerland
$273K +$71.8K +2,078 +36%
AQR Capital Management
112
AQR Capital Management
Connecticut
$272K -$80.3K -2,322 -23%
Mariner
113
Mariner
Kansas
$248K +$246K +7,128 New
AB
114
Amalgamated Bank
New York
$247K +$31.1K +901 +14%
MC
115
Moors & Cabot
Massachusetts
$229K
Handelsbanken Fonder
116
Handelsbanken Fonder
Sweden
$222K
Rafferty Asset Management
117
Rafferty Asset Management
New York
$209K +$208K +6,017 New
JF
118
JSF Financial
California
$208K +$207K +6,000 New
Tudor Investment Corp
119
Tudor Investment Corp
Connecticut
$207K -$805K -23,271 -80%
Royal Bank of Canada
120
Royal Bank of Canada
Ontario, Canada
$203K -$231K -6,694 -53%
US Bancorp
121
US Bancorp
Minnesota
$186K -$26.4K -765 -12%
AIP
122
Ameritas Investment Partners
Nebraska
$161K +$27.1K +785 +20%
VEA
123
Virtus ETF Advisers
New York
$98.1K -$9.61K -278 -9%
MLICM
124
Metropolitan Life Insurance Company (MetLife)
New York
$95.7K +$6.26K +181 +7%
BC
125
BIT Capital
Germany
$68.4K +$68.1K +1,969 New

VTYX Hedge Fund Activity: Q3 2023 in Review

138 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q3 2023, worth a combined $1.9B — up 9.8% from $1.73B a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of VTYX and 13 opened new positions — a net loss of 10 holders — while 44 trimmed existing stakes and 61 added.

The largest buyer was Adage Capital Partners, adding an estimated $30.9M. The largest seller was Lord, Abbett & Co, cutting an estimated $20.3M.

  • 138 institutional investors held Ventyx Biosciences (VTYX) as of Q3 2023, down from 150 in Q2 2023.
  • Funds reported $1.9B of Ventyx Biosciences stock for Q3 2023, up 9.8% quarter-over-quarter.
  • 13 funds opened new Ventyx Biosciences positions in Q3 2023 and 23 closed out, a net change of -10 holders.
  • The largest Ventyx Biosciences buyer in Q3 2023 was Adage Capital Partners, an estimated $30.9M added.
  • The largest Ventyx Biosciences seller in Q3 2023 was Lord, Abbett & Co, an estimated $20.3M sold.

Based on aggregated 13F filings for Q3 2023.